Trial Profile
A Phase II Open-label, Randomized, Active-controlled Study Comparing the Efficacy and Safety of Once Daily Enfuvirtide Dosing Versus the Currently Recommended Twice Daily Dosing in HIV-1 Infected Treatment-experienced Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2015
Price :
$35
*
At a glance
- Drugs Enfuvirtide (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Roche
- 20 Oct 2006 Status change
- 13 Oct 2005 New trial record.